UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 72

Sortiert nach

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

The New England journal of medicine, 2021-05, Vol.384 (20), p.1885-1898

2021

Volltextzugriff (PDF)

Effectiveness of allergy testing in milk induced eosinophilic esophagitis. Description and follow-up of patients

Allergologia et immunopathologia, 2020-11, Vol.48 (6), p.576-581

2020

Volltextzugriff (PDF)

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial

The lancet HIV, 2021-09, Vol.8 (9), p.e568-e580

2021

Volltextzugriff (PDF)

Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005)

Vaccine, 2023-05, Vol.41 (23), p.3486-3492

2023

Volltextzugriff (PDF)

Allergies alimentaires et maladies inflammatoires de l’intestin des enfants et adolescents : y a-t-il une relation ?

Revue française d'allergologie (2009), 2013-04, Vol.53 (3), p.338-338

2013

Volltextzugriff (PDF)

Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults

Vaccine, 2008-01, Vol.26 (2), p.215-223

2008

Volltextzugriff (PDF)

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

The Lancet (British edition), 2021-04, Vol.397 (10282), p.1351-1362

2021

Volltextzugriff (PDF)

1934. Nirsevimab is Associated with Higher and More Sustained RSV Neutralizing Antibody Responses Compared with Standard of Care Palivizumab: Observations from a 2:1 Randomized, Phase 2/3 Trial in Medically Vulnerable Children (MEDLEY)

Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)

2023

Volltextzugriff (PDF)

94. Pooled analysis of nirsevimab resistance through 150 days post dose in preterm and term infants

Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)

2022

Volltextzugriff (PDF)

1953. Immune responses, viral shedding, and COVID-19 symptom burden from breakthrough SARS-CoV-2 infection in a 2:1 randomized, double-blind, placebo-controlled Phase 3 study of AZD1222 (ChAdOx1 nCoV-19) vaccination

Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)

2022

Volltextzugriff (PDF)

Oral tolerance induction with heated egg in childrena and adolescents

Clinical and translational allergy, 2013-07, Vol.3 (S3), p.P12-n/a, Article P12

2013

Volltextzugriff (PDF)

901. MEDI8897 Prevents Serious RSV Disease in Healthy Preterm Infants

Open forum infectious diseases, 2019-10, Vol.6 (Supplement_2), p.S27-S27

2019

Volltextzugriff (PDF)

LB13. The Efficacy and Impact in Heathy Infants of Nirsevimab on Medically Attended RSV Lower Respiratory Tract Infection

Open forum infectious diseases, 2021-12, Vol.8 (Supplement_1), p.S811-S812

2021

Volltextzugriff (PDF)

Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants

The New England journal of medicine, 2022-03, Vol.386 (9), p.837-846

2022

Volltextzugriff (PDF)

Enabling rapid responses to infectious diseases

Scientific American, 2022-12, Vol.327 (6), p.76

Villafana, Tonya L

2022

Volltextzugriff (PDF)

2D axial-azimuthal particle-in-cell benchmark for low-temperature partially magnetized plasmas

Plasma sources science & technology, 2019-10, Vol.28 (10), p.105010

2019

Volltextzugriff (PDF)

2D radial-azimuthal particle-in-cell benchmark for E × B discharges

Plasma sources science & technology, 2021-07, Vol.30 (7), p.75002

2021

Volltextzugriff (PDF)

A Flexible Near-Field Biosensor for Multisite Arterial Blood Flow Detection

Sensors (Basel, Switzerland), 2022-11, Vol.22 (21), p.8389

2022

Volltextzugriff (PDF)

Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants

The New England journal of medicine, 2023-04, Vol.388 (16), p.1533-1534

2023

Volltextzugriff (PDF)

Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity

The New England journal of medicine, 2022-03, Vol.386 (9), p.892-894

2022

Volltextzugriff (PDF)

A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccine

Science translational medicine, 2022-12, Vol.14 (676), p.eade0424

2022

Volltextzugriff (PDF)

Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months

The Journal of clinical investigation, 2022-09, Vol.132 (18), p.1-14

2022

Volltextzugriff (PDF)

Towards a unified genetic model for the Au-Ag-Cu Pueblo Viejo district, central Dominican Republic

Ore geology reviews, 2017-10, Vol.89, p.463-494

2017

Volltextzugriff (PDF)

Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months

The Journal of clinical investigation, 2022-09, Vol.132 (18)

2022

Volltextzugriff (PDF)

1 – 25 von 72

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(66)
Mit Volltextzugriff
(60)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

Effectiveness of allergy testing in milk induced eosinophilic esophagitis. Description and follow-up of patients

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial

Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005)

Allergies alimentaires et maladies inflammatoires de l’intestin des enfants et adolescents : y a-t-il une relation ?

Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

1934. Nirsevimab is Associated with Higher and More Sustained RSV Neutralizing Antibody Responses Compared with Standard of Care Palivizumab: Observations from a 2:1 Randomized, Phase 2/3 Trial in Medically Vulnerable Children (MEDLEY)

94. Pooled analysis of nirsevimab resistance through 150 days post dose in preterm and term infants

1953. Immune responses, viral shedding, and COVID-19 symptom burden from breakthrough SARS-CoV-2 infection in a 2:1 randomized, double-blind, placebo-controlled Phase 3 study of AZD1222 (ChAdOx1 nCoV-19) vaccination

Oral tolerance induction with heated egg in childrena and adolescents

901. MEDI8897 Prevents Serious RSV Disease in Healthy Preterm Infants

LB13. The Efficacy and Impact in Heathy Infants of Nirsevimab on Medically Attended RSV Lower Respiratory Tract Infection

Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants

Enabling rapid responses to infectious diseases

2D axial-azimuthal particle-in-cell benchmark for low-temperature partially magnetized plasmas

2D radial-azimuthal particle-in-cell benchmark for E × B discharges

A Flexible Near-Field Biosensor for Multisite Arterial Blood Flow Detection

Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants

Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity

Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials

A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccine

Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months

Towards a unified genetic model for the Au-Ag-Cu Pueblo Viejo district, central Dominican Republic

Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months

Suchergebnisse filtern